Results for: C_TS4CO_2023日本語出題内容 🐇 C_TS4CO_2023日本語全真模擬試験 🥗 C_TS4CO_2023日本語試験勉強書 🤟 ➡ www.goshiken.com ️⬅️で✔ C_TS4CO_2023日本語 ️✔️を検索して、無料で簡単にダウンロードできますC_TS4CO_2023日本語試験参考書

Sudden unexpected death with lamotrigine: risk estimate

January 11, 2012

…HE AMERICAN EPILEPSY SOCIETY 65TH ANNUAL MEETING, BALTIMORE, MD, DECEMBER 2-6, 2011 – A Norwegian study estimates that the risk of sudden unexpected death in epilepsy (SUDEP) is 2.5 per 1000 patient-years in female patients receiving lamotrigine compared to 0.5 per 1000 patient-years in women not on lamotrigine (Aurlien et al. AES 2011; abstract 3.205). Subscribe to read more It takes 30 seconds or login using your email address Please enter the e…

Potassium channel activator useful in partial-onset seizures

December 14, 2011

…Retigabine (ezogabine in the U.S.), which activates KCNQ2/2 potassium channels, is effective as an adjunctive treatment in partial-onset seizures, according to the results of the phase III RESTORE 1 trial (French et al. Neurology 2011; 76: 1555-1563). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

ADAPT trial update: NSAIDs in AD

December 14, 2011

…Research Group et al. Alzheimers Dement 2009; 5: 93-104; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2866447/pdf/nihms185404.pdf). The trial was suspended in 2004 following the finding from the Adenoma Prevention with Celecoxib (APC) trial of an increased cardiovascular risk with celecoxib (Solomon et al. N Engl J Med 2005; 352: 1071-1080; free full text at www.nejm.org/doi/full/10.1056/NEJMoa050405). Subscribe to read more It takes 30…

CONFIRM – Second phase III trial results for BG-12

November 30, 2011

…OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – Just days after ECTRIMS, top-line results from the second of two phase III trials of BG-12 were announced in a press release (www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1621631) and in a webcast to investors (www.biogenidec.com/investors.aspx?ID=5494). Subscribe to read more It takes 30 seconds o…